Recent Development of Nuclear Molecular Imaging in Thyroid Cancer-Reference-Cited by-同舟云学术

Recent Development of Nuclear Molecular Imaging in Thyroid Cancer

Published:2018 Issue: Volume:2018 Page:1-10
ISSN:2314-6133
Container-title:BioMed Research International
language:en
Short-container-title:BioMed Research International

Author:

Liu Huiting¹,Wang Xiaoqin²,Yang Ran³,Zeng Wenbing³,Peng Dong¹^ORCID,Li Jason⁴,Wang Hu⁴⁵^ORCID

Affiliation:

1. Department of Nuclear Medicine, Chongqing Three Gorges Central Hospital, Wanzhou 404000, China

2. Clinical Test Center, Chongqing Three Gorges Central Hospital, Wanzhou 404000, China

3. Department of Radiology, Chongqing Three Gorges Central Hospital, Wanzhou 404000, China

4. Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

5. Medical School, China Three Gorges University, Yichang 443002, China

Abstract

Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes, cellular processes, and tumor microenvironment, molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the most common endocrine malignancy, and its theranostic radioiodine has been widely used to diagnose or treat differentiated thyroid cancer. This article summarizes recent development of molecular imaging in thyroid cancer, which may accelerate the development of personalized thyroid cancer therapy.

Funder

National Natural Science Foundation of China

Publisher

Hindawi Limited

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://downloads.hindawi.com/journals/bmri/2018/2149532.pdf

Reference95 articles.

1. Molecular imaging in thyroid cancer

2. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005

3. Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back